Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | PKM | P14618 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30352917 | 1.00 | MAPT (0.53) | MAPTALDH1A1PKMHTTL3MBTL1 | |
| SCHEMBL20163174 | 0.84 | MAPT (0.54) | MAPTALDH1A1PKMHTTL3MBTL1 | |
| SCHEMBL8824439 | 0.83 | CYP1A2 (0.51) | MAPTALDH1A1PKMHTTL3MBTL1 | |
| SCHEMBL762458 | 0.83 | KMT2A (0.54) | MAPTALDH1A1PKMHTTL3MBTL1 | |
| SCHEMBL30352910 | 0.81 | POLB (0.45) | MAPTALDH1A1PKMHTTL3MBTL1 | |
| SCHEMBL7269702 | 0.80 | MAPT (0.66) | MAPTALDH1A1PKMHTTL3MBTL1 | |
| SCHEMBL1176657 | 0.78 | LMNA (0.64) | MAPTALDH1A1PKML3MBTL1KMT2A | |
| SCHEMBL1176655 | 0.78 | LMNA (0.64) | MAPTALDH1A1PKML3MBTL1KMT2A | |
| SCHEMBL2655373 | 0.78 | LMNA (0.45) | MAPTALDH1A1PKMHTTL3MBTL1 | |
| SCHEMBL2655371 | 0.78 | LMNA (0.45) | MAPTALDH1A1PKMHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-18 | — | — | US | disclosed |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, HCCS, CFTR | MAPT 4548/4885ALDH1A1 629/4885PKM 1053/4885 |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | MAPT 4548/4885ALDH1A1 629/4885PKM 1053/4885 |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | MAPT 4548/4885ALDH1A1 629/4885PKM 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.